Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Jun;83(6):1147-1158.
doi: 10.1007/s00280-019-03826-1. Epub 2019 Apr 11.

Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study

Whitney P Kirschbrown  1 , Matts Kågedal  1 , Bei Wang  1 , Lars Lindbom  2 , Adam Knott  3 , Rachelle Mack  3 , Sharareh Monemi  1 , Ihsan Nijem  1 , Sandhya Girish  1 , Christie Freeman  4 , Debora Fumagalli  5 , Robin McConnell  6 , Guy Jerusalem  7 , Chris Twelves  8 , José Baselga  9 , Gunter von Minckwitz  10 , José Bines  11 , Amit Garg  12
Affiliations
Clinical Trial

Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study

Whitney P Kirschbrown et al. Cancer Chemother Pharmacol. 2019 Jun.

Abstract

Purpose: To characterize the pharmacokinetics (PK) of, and perform an exploratory exposure-response (E-R) analysis for, pertuzumab in patients with HER2-positive early breast cancer (EBC) within the APHINITY study (NCT01358877, BIG 4-11/BO25126/TOC4939G).

Methods: A previously developed pertuzumab two-compartment linear population pharmacokinetic (popPK) model was subjected to external validation to examine appropriateness for describing pertuzumab concentrations from the APHINITY study. Pharmacokinetic drug-drug interactions (DDIs) between pertuzumab, trastuzumab, and chemotherapy were assessed by comparing observed serum or plasma Cmax, Cmin, and AUClast geometric mean ratios with 90% CIs. Predictions of pertuzumab Cmax,ss, Cmin,ss, and AUCss were derived from individual parameter estimates and used in an exploratory E-R analysis.

Results: Using data from 72 patients, based on goodness-of-fit, the popPK model was deemed appropriate for predictions of individual exposures for subsequent comparisons to historical data, assessment of DDIs, and E-R analyses. No evidence of DDIs for pertuzumab on trastuzumab, trastuzumab on pertuzumab, or pertuzumab on chemotherapy PK was observed. Analyses of differences in exposure between patients with and without invasive disease-free survival events did not indicate improved efficacy with increased exposure. Overall Grade ≥ 3 diarrhea prevalence was higher with pertuzumab versus placebo, but was not greater with increasing pertuzumab exposure. No apparent E-R relationship was suggested with respect to other grade ≥ 3 AEs.

Conclusion: Overall, the limited available data from this exploratory study suggest that no dose adjustments are needed for pertuzumab when administered in combination with trastuzumab and an EBC chemotherapy regimen.

Keywords: Drug–drug interactions; Exposure–response; Pertuzumab; Pharmacokinetics.

PubMed Disclaimer

Conflict of interest statement

All authors received support for third-party writing assistance for this manuscript, provided by F. Hoffmann-La Roche Ltd. W.P.K. and A.G. are paid employees of Genentech, Inc., significant stockholders for Roche Holding Ltd, and inventors on a pertuzumab-related patent filing. M.K., B.W., I.N., S.M., and S.G. are paid employees of Genentech, Inc. and significant stockholders for Roche Holding Ltd. L.L. is a paid employee of, and has a significant ownership in, qPharmetra LLC. A.K. is a paid employee of Roche Products Limited and a significant stockholder for Roche Holding Ltd. R.Ma. was a paid employee of Roche Products Limited at the time of the study. D.F. received funding to run the conduct clinical trials from F. Hoffmann-La Roche Ltd/Genentech, Inc., AstraZeneca, Novartis, Servier, Tesaro, Pfizer, and GlaxoSmithKline, paid to her institution, and research grants from the charitable organizations BCRF, Foundation Cancer Luxembourg, and the Belgian National Lottery, paid to her institution. R.Mc. received funding to assist in the running of the APHINITY study from F. Hoffmann-La Roche Ltd, paid to his institution. G.J. has received honoraria from Novartis, Roche, Lilly, Pfizer, Amgen, and Bristol-Myers Squibb; holds a consulting/advisory role for Novartis, Celgene, Roche, Amgen, Pfizer, Bristol-Myers Squibb, Lilly, Puma Biotechnology, AstraZeneca, Daiichi Sankyo, and AbbVie; and has received research funding from Novartis and Roche. C.T. has received honoraria from Daiichi Sankyo, Roche, Pfizer, and Eisai, and travel expenses from MSD and Daiichi Sankyo. J.Ba. holds leadership positions in Varian Medical Systems, Bristol-Myers Squibb, Foghorn, Grail, Aura, and Infinity; consulting/advisory roles for Grail, PMV Pharma, ApoGen, Juno Therapeutics, Roche/Genentech, Lilly, Novartis, and Northern Biologics; stock or other ownership in PMV Pharma, Grail, Tango, Venthera, Juno, Varian, Foghorn, Aura, Infinity, ApoGen; and has received honoraria, travel, accommodations, and expenses from Roche/Genentech, Novartis, Lilly. G.v.M. has received research funding from Pfizer, Amgen, Celgene, AstraZeneca, Myriad Genetics, AbbVie, Vifor, and Roche, to his institution. J. Bi. has received clinical study funding from Roche as PI of the study; travel expenses to medical meetings from AstraZeneca and Roche; and holds consulting roles (advisory boards) with AbbVie, AstraZeneca, Genomic Health, Libbs, Pfizer, and Roche. C.F. declares no other conflict of interest.

Figures

Fig. 1
Fig. 1
Visual predictive check of pertuzumab concentrations. The open circles represent observed serum concentrations. The filled circles represent median observed Cmax. The filled squares represent median observed Cmin. The solid green line represents predicted median serum concentration. The shaded area represents 95% prediction interval. Cmax is maximum serum concentration. Cmin is minimum serum concentration
Fig. 2
Fig. 2
Observed versus model-predicted pertuzumab serum concentrations. The solid black line represents line of identity. The solid green line and shaded green area are Gaussian Loess smooth with 95% confidence interval. The left-panel circles are individual observations/population predictions. The right-panel circles are individual observations/individual predictions
Fig. 3
Fig. 3
Trastuzumab Cmax and Cmin with or without pertuzumab. The closed circles represent trastuzumab in the treatment arm (pertuzumab, trastuzumab, and chemotherapy). The open circles represent trastuzumab in the control arm (placebo, trastuzumab, and chemotherapy). The solid green line represents arithmetic mean for each timepoint and treatment arm. The shaded area is arithmetic mean ± 1 standard deviation. Cmax is maximum serum concentration. Cmin is minimum serum concentration
Fig. 4
Fig. 4
The relationships between pertuzumab exposure and efficacy or safety. Pertuzumab AUCss, Cmin,ss, or Cmax,ss for patients in the pertuzumab arm with or without invasive disease-free survival (IDFS) event (a), any grade ≥ 3 adverse event (AE) (b) or any grade ≥ 3 diarrhea (c). The solid green line represents arithmetic mean for each group. The shaded area represents arithmetic mean ± 1 standard deviation. AUCss is area under the concentration–time curve at steady state. Cmax,ss is maximum serum concentration at steady state. Cmin,ss is minimum serum concentration at steady state
See this image and copyright information in PMC

References

    1. Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother. 2006;55:717–727. doi: 10.1007/s00262-005-0058-x. - DOI - PMC - PubMed
    1. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002;2:127–137. doi: 10.1016/S1535-6108(02)00097-1. - DOI - PubMed
    1. Diermeier-Daucher S, Hasmann M, Brockhoff G. Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basis. Ann N Y Acad Sci. 2008;1130:280–286. doi: 10.1196/annals.1430.003. - DOI - PubMed
    1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127–137. doi: 10.1038/35052073. - DOI - PubMed
    1. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9:463–475. doi: 10.1038/nrc2656. - DOI - PubMed

Publication types

MeSH terms

Associated data